Ruixiang Li

Array ( [id] => 20264149 [patent_doc_number] => 12435125 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-10-07 [patent_title] => Hyperimmunized egg product for treating or preventing alcoholic liver disease and graft- versus-host disease [patent_app_type] => utility [patent_app_number] => 18/555338 [patent_app_country] => US [patent_app_date] => 2022-04-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 6879 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 81 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18555338 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17929841 [patent_doc_number] => 20220324966 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-13 [patent_title] => ANTIGEN-BINDING MOLECULE FOR PROMOTING CLEARANCE FROM PLASMA OF ANTIGEN COMPRISING SUGAR CHAIN RECEPTOR-BINDING DOMAIN [patent_app_type] => utility [patent_app_number] => 17/716467 [patent_app_country] => US [patent_app_date] => 2022-04-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 76654 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17716467 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18227346 [patent_doc_number] => 20230066340 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-02 [patent_title] => POPULATIONS OF ENRICHED REGULATORY T CELLS AND METHODS FOR PRODUCING SAME [patent_app_type] => utility [patent_app_number] => 17/704623 [patent_app_country] => US [patent_app_date] => 2022-03-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40299 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 168 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17704623 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19809516 [patent_doc_number] => 12240887 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-03-04 [patent_title] => Variant ActRIIB proteins and uses thereof [patent_app_type] => utility [patent_app_number] => 17/687934 [patent_app_country] => US [patent_app_date] => 2022-03-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 62453 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17687934 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17672734 [patent_doc_number] => 20220185901 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-16 [patent_title] => Bispecific antibodies binding ALK-1 and BMPR-2 [patent_app_type] => utility [patent_app_number] => 17/681573 [patent_app_country] => US [patent_app_date] => 2022-02-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21010 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17681573 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18209384 [patent_doc_number] => 20230055644 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-23 [patent_title] => T-CELL MODULATORY CHIMERIC MOLECULES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/678748 [patent_app_country] => US [patent_app_date] => 2022-02-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 58115 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17678748 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18209384 [patent_doc_number] => 20230055644 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-23 [patent_title] => T-CELL MODULATORY CHIMERIC MOLECULES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/678748 [patent_app_country] => US [patent_app_date] => 2022-02-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 58115 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17678748 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17776578 [patent_doc_number] => 20220242927 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-04 [patent_title] => ALK4:ACTRIIB HETEROMULTIMERS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/666705 [patent_app_country] => US [patent_app_date] => 2022-02-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 63310 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17666705 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19731145 [patent_doc_number] => 12209136 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-01-28 [patent_title] => ADAMTS binding immunoglobulins [patent_app_type] => utility [patent_app_number] => 17/579345 [patent_app_country] => US [patent_app_date] => 2022-01-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 23 [patent_no_of_words] => 43517 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 493 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17579345 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17533670 [patent_doc_number] => 20220112279 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-14 [patent_title] => COMPOSITIONS AND METHODS FOR TARGETING ACTIVIN SIGNALING TO TREAT CANCER [patent_app_type] => utility [patent_app_number] => 17/561496 [patent_app_country] => US [patent_app_date] => 2021-12-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21439 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17561496 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17533690 [patent_doc_number] => 20220112299 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-14 [patent_title] => AGONISTIC ANTI-TUMOR NECROSIS FACTOR RECEPTOR 2 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/561448 [patent_app_country] => US [patent_app_date] => 2021-12-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42124 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -124 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17561448 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17680036 [patent_doc_number] => 11364267 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2022-06-21 [patent_title] => Bi-specific targeting human NKG2DL and CLDN18A2 chimeric antigen receptor cells, preparation method and application thereof [patent_app_type] => utility [patent_app_number] => 17/551147 [patent_app_country] => US [patent_app_date] => 2021-12-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 24 [patent_no_of_words] => 7772 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17551147 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18399333 [patent_doc_number] => 11661459 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-05-30 [patent_title] => Artificial cell death polypeptide for chimeric antigen receptor and uses thereof [patent_app_type] => utility [patent_app_number] => 17/457142 [patent_app_country] => US [patent_app_date] => 2021-12-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 46 [patent_figures_cnt] => 52 [patent_no_of_words] => 40193 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 80 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17457142 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20108285 [patent_doc_number] => 12358993 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-15 [patent_title] => Methods for the treatment of thyroid eye disease [patent_app_type] => utility [patent_app_number] => 17/531368 [patent_app_country] => US [patent_app_date] => 2021-11-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21072 [patent_no_of_claims] => 39 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 120 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17531368 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20108285 [patent_doc_number] => 12358993 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-15 [patent_title] => Methods for the treatment of thyroid eye disease [patent_app_type] => utility [patent_app_number] => 17/531368 [patent_app_country] => US [patent_app_date] => 2021-11-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21072 [patent_no_of_claims] => 39 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 120 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17531368 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19731139 [patent_doc_number] => 12209130 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-01-28 [patent_title] => Methods for the treatment of thyroid eye disease [patent_app_type] => utility [patent_app_number] => 17/531365 [patent_app_country] => US [patent_app_date] => 2021-11-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 24916 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17531365 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18172710 [patent_doc_number] => 11572407 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-02-07 [patent_title] => Anti-MARCO antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 17/529927 [patent_app_country] => US [patent_app_date] => 2021-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 80 [patent_figures_cnt] => 126 [patent_no_of_words] => 75978 [patent_no_of_claims] => 58 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 133 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17529927 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17458798 [patent_doc_number] => 20220072102 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-10 [patent_title] => TREATMENT OF INFLAMMATORY CONDITIONS BY DELIVERY OF INTERLEUKIN-1 RECEPTOR ANTAGONIST FUSION PROTEIN [patent_app_type] => utility [patent_app_number] => 17/527956 [patent_app_country] => US [patent_app_date] => 2021-11-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22038 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17527956 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19593143 [patent_doc_number] => 12150961 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-11-26 [patent_title] => Therapies with lanthionine C-like protein 2 ligands and cells prepared therewith [patent_app_type] => utility [patent_app_number] => 17/524883 [patent_app_country] => US [patent_app_date] => 2021-11-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 35 [patent_figures_cnt] => 35 [patent_no_of_words] => 22066 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 420 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17524883 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19969681 [patent_doc_number] => 12338273 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-06-24 [patent_title] => Single-arm type I and type II receptor fusion proteins and uses thereof [patent_app_type] => utility [patent_app_number] => 17/523226 [patent_app_country] => US [patent_app_date] => 2021-11-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 56018 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 138 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17523226 [rel_patent_id] =>[rel_patent_doc_number] =>)